Beckmann K - Search Results

1

PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.

Ahlberg MS, Adami HO, Beckmann K, Bertilsson H, Bratt O, Cahill D, Egevad L, Garmo H, Holmberg L, Johansson E, Rannikko A, Van Hemelrijck M, Jäderling F, Wassberg C, Åberg UWN, Bill-Axelson A. Ahlberg MS, et al. Among authors: beckmann k. BMJ Open. 2019 Aug 22;9(8):e027860. doi: 10.1136/bmjopen-2018-027860. BMJ Open. 2019. PMID: 31444180 Free PMC article.

2

A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.

Russell B, Garmo H, Beckmann K, Stattin P, Adolfsson J, Van Hemelrijck M. Russell B, et al. Among authors: beckmann k. PLoS One. 2018 Apr 12;13(4):e0195690. doi: 10.1371/journal.pone.0195690. eCollection 2018. PLoS One. 2018. PMID: 29649268 Free PMC article.

3

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Van Hemelrijck M, et al. Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29. Eur Urol. 2019. PMID: 30385049 Free PMC article.

4

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M. Beckmann K, et al. Eur Urol. 2019 Apr;75(4):676-683. doi: 10.1016/j.eururo.2018.11.022. Epub 2018 Nov 26. Eur Urol. 2019. PMID: 30497883

5

Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study.

Beckmann K, Russell B, Josephs D, Garmo H, Haggstrom C, Holmberg L, Stattin P, Van Hemelrijck M, Adolfsson J. Beckmann K, et al. BMC Cancer. 2019 Jun 21;19(1):612. doi: 10.1186/s12885-019-5846-3. BMC Cancer. 2019. PMID: 31226970 Free PMC article.

6

A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer.

Kinsella N, Beckmann K, Cahill D, Elhage O, Popert R, Cathcart P, Challacombe B, Brown C, Van Hemelrijck M. Kinsella N, et al. Among authors: beckmann k. Eur Urol Oncol. 2019 Jul;2(4):464-470. doi: 10.1016/j.euo.2018.09.007. Epub 2018 Oct 11. Eur Urol Oncol. 2019. PMID: 31277784 Clinical Trial.

7

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?

Beckmann K, Kinsella N, Olsson H, Wallerstedt Lantz A, Nordstrom T, Aly M, Adolfsson J, Eklund M, Van Hemelrijck M. Beckmann K, et al. BMC Urol. 2019 Aug 5;19(1):73. doi: 10.1186/s12894-019-0502-4. BMC Urol. 2019. PMID: 31383015 Free PMC article.

8

Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium. Drost FH, et al. Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24. Eur Urol. 2019. PMID: 31451332

9

Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.

Kalapara AA, Verbeek JFM, Nieboer D, Fahey M, Gnanapragasam V, Van Hemelrijck M, Lee LS, Bangma CH, Steyerberg EW, Harkin T, Helleman J, Roobol MJ, Frydenberg M; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Kalapara AA, et al. Eur Urol Oncol. 2020 Feb;3(1):80-91. doi: 10.1016/j.euo.2019.08.014. Epub 2019 Sep 26. Eur Urol Oncol. 2020. PMID: 31564531

10

Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.

Beckmann K, Crawley D, Nordström T, Aly M, Olsson H, Lantz A, Binti Abd Jalal N, Garmo H, Adolfsson J, Eklund M, Van Hemelrijck M. Beckmann K, et al. JAMA Netw Open. 2019 Nov 1;2(11):e1914689. doi: 10.1001/jamanetworkopen.2019.14689. JAMA Netw Open. 2019. PMID: 31693126 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters